Summary
Ergot compounds may affect endocrine systems through stimulatory and inhibitory dopamine receptors at the hypothalamic and the pituitary level. In most cases, with the exception of the prolactin and the melanotropin cell receptors, the characterization of the dopamine receptor involved is not yet satisfactory. Comparing in vivo or in vitro dopaminomimetic activities of ergot compounds produces a multiplicity of profiles of actions without a clear pattern.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adams, E. F., Ashby, M.J., Brown, S. M., White, M. C., Mashiter, K.: Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin. Endocrinol. 15, 479–484 (1981).
Agnati, L., Fuxe, K., Löfström, A., Hökfelt, T: Dopaminergic drugs and ovulation: Studies on PMS-induced ovulation and changes in median eminence DA and NE turnover in immature female rats. In: Advances in Biochemical Psychopharmacology (Costa, E., Gessa, G. L., eds.), p. 159. New York: Raven Press. 1977.
Bansal, S., Woolf, P. D., Fischer, J.A., Caro, J. F.: Dopamine does not affect parathyroid function in man. J. Clin. Endocrinol. Metab. 54, 651–652 (1982).
Bethea, C. L., Ramsdell, J. S.,Jaffe, R. B., Wildson, C. B., Weiner, R.I.: Characterization of the dopaminergic regulation of human prolactin secreting cells cultured on extracellular matrix. J. Clin. Endocrinol. Metab. 54, 893–902 (1982).
Bevilacqua, M., Vago, T, Malacco, E., Norblato, G.: Characterization of dopaminergic receptors in calf adrenal glomerulosa cells. Abstract, Symp. on Dopamine Receptor Agonists, Stockholm, April 20–23, 1982.
Bisset, G. W.: The milk ejection reflex. In: Neurohypophysial Hormones and Similar Peptides (Berde, B., ed.) (Handbook of Exp. Pharmacology, Vol. XXIII), p. 475. Berlin-Heidelberg-New York: Springer. 1968.
Blum, J. W., Kunz, P., Fischer, J. A., Binswanger, U., Lichtensteiger, W, da Prada, M.: Parathyroid hormone response to dopamine in cattle. Am. J. Physiol. 239, 255–264 (1980).
Bression, D., Brandi, A. M., Nousbaum, A., LeDafniet, M., Racadot, J., Peilion, F.: Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifused system. J. Clin. Endocrinol. Metab. 55, 589–593 (1982).
Bridges, T.E., Hillhouse, E. W., Jones, M. T: The effect of dopamine on neurohypophysial hormone release in vivo and from the rat neural lobe and hypothalamus in vitro. J. Physiol. 260, 647–666 (1976).
Brown, E. M., Caroll, R.J., Aurbach, G. D.: Dopaminergic stimulation of cyclic AMP accumulation and parathyroid hormone release from dispersed bovine parathyroid cells. Proc. Natl. Acad. Sci. USA 74, 4210–4213 (1977).
Calabro, M.A., MacLeod, R.M.: Binding of dopamine to bovine anterior pituitary gland membranes. Neuroendocrinology 25, 32–46 (1976).
Camanni, F., Massara, F., Belforte, L., Molinatti, G. M.: Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-a-ergokryptine. J. Clin. Endocrinol. Metab. 40, 363–366 (1975).
Carey, R. M., Thorner, M. O.: Dopaminergic inhibition of metoclopramide induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine. J. Clin. Invest. 66, 10–15 (1980).
Carey, R. M., Thorner, M. O., Ortt, E.: Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. J. Clin. Invest. 66, 10–18 (1980).
Carey, R. M., Van Loon, G. R.: Bromocriptine does not inhibit the aldosterone response to sodium depletion. J. Clin. Endocrinol. Metab. 55, 162–165 (1982).
Caron, G. M., Beaulieu, M., Raymond, V., Gagne, B., Drouin, J., Lefkowitz, J., Labrie, F.: Dopaminergic receptors in the anterior pituitary gland. J. Biol. Chem. 253, 2244–2253 (1978).
Clarke, G., Lincoln, D. W, Merrick, L.P.: Dopaminergic control of oxytocin release in lactating rats. J. Endocr. 83, 409–420 (1979).
Connell, J. M. C.: Bromocriptine for inappropriate thyrotropin secretion. Ann. Intern. Med. 96, 251–252 (1982).
Cote, T. E., Grewe, C. W, Kebabian, J. W: Stimulation of a D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland decreases the responsiveness of the ß-adrenoceptor: Biochemical mechanism. Endocrinology 108, 420–426 (1981).
Cronin, M.J.: The role and direct measurement of the dopamine receptor(s) in the anterior pituitary. In: Neuroendocrine Perspectives, Vol.1 (Müller, E.E., MacLeod, R.M., eds.), p. 169. Amsterdam: Elsevier Biomedical Press. 1982.
Cronin, M.J.: Some calcium and lysosome antagonists inhibit 3H-spiperone binding to the porcine anterior pituitary. Life Sci. 30, 1385–1389 (1982).
Cronin, M.J., Cheung, C. Y, Wilson, C. B., Jaffe, R. B., Weiner, R. I.: [3H]-spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin, growth hormone, and adrenocorticotropic hormone. J. Clin. Endocrinol. Metab. 50, 387–391 (1980).
Delitala, G., Yeo, T, Grossman, A., Hathway, N. R., Besser, G. M.: A comparison of the effects of four ergot derivatives on prolactin secretion by dispersed rat pituitary cells. J. Endocr. 87, 95–103 (1980).
del Pozo, E., Lancranjan, I.: Clinical use of drugs modifying the release of anterior pituitary hormones. In: Frontiers in Neuroendocrinology (Ganong, W F., Martini, L., eds.), Vol. 5, p. 207. New York: Raven Press. 1978.
del Pozo, E., Darragh, A., Lancranjan, 1., Ebeling, D., Burmeister, P., Bühler, F., Marbach, P., Braun, P.: Effect of bromocriptine on the endocrine system and fetal development. Clin. Endocrinol. 6 (Suppl.), 47–55 (1977).
Denef, C., Baes, M.: ß-Adrenergic stimulation of prolactin release from superfused pituitary aggregates. Endocrinology 111, 356–358 (1982).
El-Denshary, E. E., Ismail, N. A., Gagesman, E., Sehling, J., Täl edal, L-B.: Bromocriptine and insulin secretion. Bioscience Reports 2, 115–116 (1982).
Evans, W. S., Rogol, A. D., MacLeod, R.M., Thorner, M. O.: Dopaminergic mechanism and luteinizing hormone secretion. I. Acute administration of the dopamine agonist bromocriptine does not inhibit luteinizing hormone release in hyperprolactinemic women. J. Clin. Endocrinol. 50, 103–107 (1980).
Evans, W. S., Cronin, M.J., Thorner, M. O.: Hypogonadism in hyperprolactinemia: Proposed mechanism. In: Frontiers in Neuroendocrinology (Ganong, W. F., Martini, L., eds.), Vol. 7, p. 77. New York: Raven Press. 1982.
Flückiger, E.: Lactation inhibition by ergot drugs. In: Physiology of Mammary Glands (Yokoyama, A., Mizouno, H., Nagasawa, H., eds.), p.71. Tokyo: Japan Scientific Societies Press/Baltimore: University Park Press. 1978.
Flückiger, E.: Ergots and endocrine functions. In: Ergot Compounds and Brain Function. Neuroendocrine and Neuropsychiatric Aspects (Goldstein, M., Calne, D. B., Liebermann, A., Thorner, M. O., eds.), p. 155. New York: Raven Press. 1980.
Flückiger, E.: Inhibitors of prolactin secretion. In: Advances in Pharmacology and Therapeutics II, Vol. 1: CNS Pharmacology, Neuropeptides (Yoshida, H., Hagihara, Y., Ebashi, S., eds.), pp. 129. Oxford: Pergamon Press. 1982.
Flückiger, E., del Pozo, E.: Influence on the endocrine system. In: Ergot Alkaloids and Related Compounds (Berde, B., Schild, H. U., eds.) (Handbook of Experimental Pharmacology, Vol.49), p. 615. Berlin-HeidelbergNew York: Springer. 1978.
Flückiger, E., Vigouret, J.-M., Wagner, H.-R.: Ergot compounds and prolactin secretion. In: Progress in Prolactin Physiology and Pathology (Robyn, C., Harter, M., eds.), p. 383. Amsterdam: Elsevier/North-Holland Biomedical Press. 1978.
Flückiger, E., Vigouret, J.-M.: Drugs, dopamine and pituitary secretion. In: Medicinal Chemistry VI, Proc. 6th Internat. Symp. Med. Chem., Brighton, 1978 (Simkins, M. A., ed.), p. 469. Oxford: Cotswold Press. 1979.
Flückiger, E., Briner, U., Bürki, H.R., Marbach, P., Wagner, H-R., Doepfner, W.: Two novel prolactin release-inhibiting 8a-amino-ergolines. Experientia 35, 1677–1678 (1979).
Flückiger, E., del Pozo, E.: Ergot derivatives and pituitary hormones. In: Neuroactive Drugs in Endocrinology (Müller, E.E., ed.), p. 169. Amsterdam: Elsevier/North-Holland Biomedical Press. 1980.
Flückiger, E., Briner, U., Kovacs, E., Markstein, R., Stürmer, E., Vigouret, J.-M., Wagner, H.-R.: Prolactin secretion stimulation by an ergopeptine. Experientia 37, 669 (1981).
Flückiger, E., Briner, U., Enz, A., Markstein, R., Vigouret, J.-M.: Dopaminergic ergot compounds: An overview. In: Lisuride and Other Dopamine Agonists: Basic Mechanisms and Endocrine and Neurological Effects (Calne, D. B., Horowski, R., McDonald, R., Wuttke, W., eds.), p. 1–9. New York: Raven Press. 1982.
Flückiger, E., del Pozo, E., von Werder, K.: Prolactin, Physiology, Pharmacology and Clinical Findings. (Monographs on Endocrinology, Vol. 23.) BerlinHeidelberg-New York: Springer. 1982 b.
Flückiger, E., Markstein, R.: Receptor pharmacology of ergot compounds. In: Human Prolactin (Tolis, G., ed). New York: Raven Press. 1982 (in press).
Foord, S. M., Peters, Scanlon, M. F., Bees Smith, B., Hall, R.: Dopaminergic control of TSH secretion in isolated rat pituitary cells. FEBS Letters 121, 257–259 (1980).
Grossman, A., Yeo, T, Delitala, G., Hathway, N. R., Besser, G. M.: Two new dopamine agonists that are long acting in vivo but short acting in vitro. Clin. Endocrinol. 13, 595–599 (1980).
Hauth, H.: Chemical aspects of ergot derivatives with central dopaminergic activity. In: Dopaminergic Ergot Derivatives and Motor Function (Fuze, K., Caine, D.B., eds.), p. 23. Oxford: Pergamon Press. 1979.
Kebabian, J. W., Calne, D.B.: Multiple receptors for dopamine. Nature 277, 93–96 (1979).
Kerdelhue, B., Weisman, A. S., Weiner, R. I.: A dopaminergic binding site in the high speed supernatant of steer anterior pituitary homogenates. Endocrinology 109, 307–309 (1981).
Köbberling, J., Darragh, A., del Pozo, E.: Chronic dopamine receptor stimulation using bromocriptine: Failure to modify thyroid function. Clin. Endocrinol. 11, 367–370 (1979).
Krulich, L.: Neurotransmitter control of thyrotropin secretion. Neuroendocrinology 35, 139–147 (1982).
Labrie, F., Borgeat, P., Drouin,J., Lagace, L., Giguere, V., Raymond, V., Godbout, M., Massicotte,J., Ferland, Barden, N., Beaulieu, M., Cote,J., Lepine,J., Meunier, H., Veileux, R.: The role of cyclic nucleotides in the control of anterior pituitary gland activity. In: Cyclic Nucleotides II (Kebabian, J. W., Nathanson,J.A., eds.), p. 525. Berlin-Heidelberg-New York: Springer. 1982.
Lachelin, G. C. L., Leblanc, H., Yen, S. S. C.: The inhibitory effect of dopamine agonists on LH release in women. J. Clin. Endocrinol. Metab. 44, 728–732 (1977).
Lal, S., de la Vega, C. E., Sourkes, T. L., Friesen, H. G.: Effect of apomorphine on human growth hormone secretion. Lancet II, 661 (1972).
Lauer, C. G., Braley, L.A., Menachery, A.I., Williams, G. H.: Metoclopramide inhibits aldosterone biosynthesis in vitro. Endocrinology 111, 238–243 (1982).
Lawton, N. F., Evans, A.J., Weller, R. O.: Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary. J. Neurol. Sci. 49, 229–239 (1981).
Leblanc, H., Lachelin, G. C. L., Abu-Fadil, S., Yen, S. S. C.: Effects of dopamine infusion on pituitary hormone secretion in humans. J. Clin. Endocrinol. Metab. 43, 668–674 (1976).
Lincoln, D. W, Paisley, A. C.: Neuroendocrine control of milk ejection. J. Reprod. Fert. 65, 571–586 (1982).
Liuzzi, A., Chiodini, P. G., Botalla, L., Cremascoli, G., Silvestrini, F.: Inhibitory effect of L-DOPA on GH release in acromegalic patients. J. Clin. Endocrinol. Metab. 35, 941–943 (1972).
Liuzzi, A., Chiodini, P. G., Botalla, L., Cremascoli, G., Müller, E. E.: Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 administration. J. Clin. Endocrinol. Metab. 38, 910–912 (1974).
Liuzzi, A., Panerai, A. E., Chiodini, P. G., Secchi, C., Cocchi, D., Botalla, L., Silvestrini, F., Müller, E. E.: Neuroendocrine control of growth hormone secretion: Experimental and clinical studies. In: Growth Hormone and Related Peptides (Peelle, A., Müller, E. E., eds.), p. 236. Amsterdam: Excerpta Medica. 1976.
MacLeod, R. M.: Regulation of prolactin secretion. In: Frontiers in Neuroendocrinology, Vol. IV (Martini, L., Ganong, W. F., eds.), p. 169. New York: Raven Press. 1976.
Marko, M., Flückiger, E.: Inhibition of spontaneous and induced ovulation in rats by non-steroidal agents. Experientia 30, 1174–1176 (1974).
Marko, M., Flückiger, E.: Role of serotonin in the regulation of ovulation. Evidence for pharmacological studies. Neuroendocrinology 30, 228–231 (1980).
Markovitz, S., Goodyer, C. G., Guyda, H., Gardiner, R.J., Hardy, J.: Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture. J. Clin. Endocrinol. Metab. 54, 6–16 (1982).
Markstein, R.: Neuroendocrine effects of some ergot derivatives. A basis for their antiparkinson actions. J. Neural Transm. 51, 39–59 (1981).
Martin, W. H., Rogol, A.D., Kaiser, D.L., Thorner, M. O.: Dopaminergic mechanism and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. J. Clin. Endocrinol. Metab. 52, 650–656 (1981).
Mashiter, K., Adams, E., Beard, M., Holley, A.: Bromocriptine inhibits prolactin and growth hormone release by human pituitary tumours in culture. Lancet 11, 197–198 (1977).
Massara, F., Camanni, F., Belforte, L., Molinatti, G. M.: Dopamine-induced inhibition of prolactin and growth hormone secretion in acromegaly. Lancet 1, 485 (1976).
Massara, F., Camanni, F., Belforte, L., Molinatti, G. M.: Dopamine and inhibition of prolactin and growth hormone secretion. Lancet 1, 913 (1976).
Maurer, R. A.: Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J. Biol. Chem. 255, 8092–8097 (1980).
Maurer, R.A. (1981): Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294, 94–97 (1981).
Maurer, R. A.: Adenosine 3’, 5’-monophosphate derivatives increase prolactin synthesis and prolactin messenger ribonucleic acid levels in ergocryptine-treated pituitary cells. Endocrinology 110, 1957–1963 (1982).
Moos, F., Richard, Ph.: Effects of dopaminergic antagonists and agonists on oxytocin release induced by various stimuli. Neuroendocrinology 28, 138–144 (1979).
Munemura, M., Cote, T. E., Tsuruta, K., Eskay, R. L., Kebabian, J. W.: The dopamine receptor in the intermediate lobe of the rat pituitary gland: Pharmacological characterization. Endocrinology 107, 1676–1683 (1980 a).
Munemura, M., Eskay, R.L., Kebabian, J. W.: Release of a-melanocytestimulating hormone from dispersed cells of the intermediate lobe of the rat pituitary gland. Involvement of catecholamines and adenosine 3’, 5’- monophosphate. Endocrinology 106, 1795–1803 (1980 b).
Nansel, D. D., Gudelsky, G.A., Reymond, M.J., Neaves, W.B., Porter, J. C.: A possible role for lysosomes in the inhibitory action of dopamine on prolactin release. Endocrinology 108, 896–902 (1981).
Penny, R.J., Thody, A.J.: Preliminary studies on the control of a-melanocytestimulating hormone secretion in the rat. J. Endocr. 69, 2–3 (1976).
Penny, R.J., Tilders, F.J. H., Thody, A.J.: The role of the dopaminergic tuberohypophyseal neurones in the maintenance of “basal” melanocyte-stimulating hormone levels in the rat. J. Endocrinol. 80, 58–59 (1979).
Perryman, R. L., Rogol, A. D., Kaiser, D. L., MacLeod, R. M., Thorner, M. O.: Pergolide mesylate: Its effects on circulating anterior pituitary hormones in man. J. Clin. Endocrinol. Metab. 53, 772–778 (1981).
Russel, J. A., Harrison, D.J., McNeilly, A. S.: Bromocriptine and a-ergocryptine do not inhibit oxytocin secretion in the lactating rat. J. Endocr. 89, 91–98 (1981).
Sarkar, D.K., Fink, G.: Gonadotropin-releasing hormone surge: possible modulation through postsynaptic a-adrenoceptors and two pharmacologically distinct dopamine receptors. Endocrinology 108, 862–867 (1981).
Scatton, B.: Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: Evidence against dopamine receptor multiplicity. J. Pharmacol. Exp. Therap. 220, 197–202 (1982).
Scholtysik, G., Müller-Schweinitzer, E.: Evidence of presynaptic dopamine receptors in sympathetic heart nerves of cats. In: Modulation of Neurochemical Transmission (Vizi, E. S., ed.), p.189. London: Pergamon Press/ Budapest: Akadémiai Kiad 6. 1980.
Seybold, V. S., Miller, J. W., Lewis, P. R.: Investigation of a dopaminergic mechanism for regulating oxytocin release. J. Pharmacol. Exp. Ther. 207, 605–610 (1978).
Thorner, M. O., Ryan, S. M., Wass, J. A. H., Jones, A., Bouloux, P., Williams, S., Besser, G. M.: Effect of the dopamine agonist lergotrile mesylate, on circulating anterior pituitary hormones in man. J. Clin. Endocrinol. Metab. 47, 372 (1978).
Thorner, M. O., Flückiger, E., Calne, D. B.: Bromocriptine, A Clinical and Pharmacological Review. New York: Raven Press. 1980.
Tolis, G., Pinter, E.J., Friesen, H. G.: The acute effect of 2-bromo-a-ergokryptine (CB 154) on anterior pituitary hormones and free fatty acids in man. J. Clin. Pharmacol. 12, 281–283 (1975).
Tsuruta, K., Frey, E.A., Grewe, C. W, Cote, T. E., Eskay, R.L., Kebabian, J. W.: Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292, 463–465 (1981).
Verde, G., Oppizzi, G., Colussi, G., Cremascoli, G., Botala, L., Müller, E. E., Silvestrini, F., Chiodini, P. G., Liuzzi, A.: Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in acromegalic patients. Clin. Endocrinol. 5, 419–423 (1976).
Vesely, D. L.: Bromocriptine enhances guanylate cyclase activity. Endocrinology 109, 1284–1286 (1981).
Vigouret, J. M., Bürki, H. R., Jaton, A. L., Züger, P. E., Loew, D. M.: Neurochemical and neuropharmacological investigations with four ergot derivatives. Pharmacology 16 (Suppl. 1), 156–173 (1978).
Wass, J. A. H., Clemmons, D. R., Underwood, L. E., Barrow, I., Besser, G. N., Van Wyk, J.J.: Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clinical Endocrinol. (in press).
Weiner, R. I., Ganong, W. F.: Role of brain monoamines and histamine in regulation of anterior pituitary secretion. Physiol. Revs. 58, 905–976 (1978).
Woolf, P.D.: Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. Am. J. Physiol. 240, 700–704 (1981).
Yeo, T., Thorner, M. O.,Jones, A., Lowry, P.J., Besser, G. M.: The effects of dopamine, bromocriptine, lergotrile and metoclopramide on prolactin release from continuously perfused columns of isolated rat pituitary cells. Clin. Endocrinol. 10, 123–130 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Wien
About this paper
Cite this paper
Flückiger, E. (1983). Interactions of Ergot Compounds with Dopamine Receptors and Endocrine Functions. In: Goldstein, M., Jellinger, K., Riederer, P. (eds) Basic Aspects of Receptor Biochemistry. Journal of Neural Transmission, vol 18. Springer, Vienna. https://doi.org/10.1007/978-3-7091-4408-4_18
Download citation
DOI: https://doi.org/10.1007/978-3-7091-4408-4_18
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-4410-7
Online ISBN: 978-3-7091-4408-4
eBook Packages: Springer Book Archive